hepatitis B

RNA interference (RNAi) is a fundamental gene-silencing pathway in eukaryotic cells that involves an enzyme called dicer cleaving long pieces of double-stranded RNA into shorter fragments called siRNAs that can cleave complementary mRNA sequences with the help of the RISC complex and argonaute. RNA interference ...

Actinium Announces Positive Top-line Results from Pivotal Phase III SIERRA Trial of Iomab-B Actinium Pharma is on track to submit its targeted radiotherapy for AML patients requiring a bone marrow transplant in the United States, boosted by top-line data from a pivotal trial. The SIERRA trial of Iomab-B, an anti...

Bristol-Myers Squibb’s Opdivo and Yervoy Combo Fails in Phase III Trial Bristol-Myers Squibb has reported that their Opdivo and Yervoy checkpoint inhibitor combo failed a phase III trial as adjuvant (post-surgery) therapy for renal cell carcinoma (RCC), the most frequent type of kidney cancer. The CheckMate -914...

Ipsen to Buy Biopharmaceutical Company Epizyme for USD 247 Million The restructuring of French manufacturer Ipsen has progressed with a takeover agreement for US competitor Epizyme and its cancer drug Tazverik in a deal for slightly less than USD 250 million. Ipsen is proposing USD 1.45 per share for Epizyme, va...

Pertussis, also commonly known as whooping cough, is a very highly contagious respiratory disease. It is caused by the bacterium Bordetella Pertussis. Pertussis can be a serious disease for people of all ages but especially for babies. Pertussis vaccines offer the best protection against this very contagious diseas...

Vir's Hepatitis B drug shows positive results in phase 2 The hepatitis B drug of Vir Biotechnology has shown promising results. Its gene-silencing drug trim levels of the hepatitis B surface antigen in a small phase 2 study in patients who are already taking antiretroviral drugs. The drug, VIR-2218,...

1 in every 100,000 persons get infected with Hepatitis B virus every year at a stable rate from the past three decades. Moreover, the WHO estimated that there are more than 2 billion HBV infected people and about 378 million chronic Hepatitis B virus carriers worldwide. Hepatitis B, often life-threatening, is a...

Orchard files for USD173 Million IPO to run pivotal gene therapy trials Orchard Therapeutics, Transatlantic biotech, has filed to raise USD 173 million in an IPO. This will lead it to take three gene therapies through the clinic. Orchard recognised itself as one of the broadest clinical-phase gene therapy pipelines ...

Key to new Cancer drugs discovered in bacterial genomes Achievement is made by the scientists of The Scripps Research Institute (TSRI) Florida campus who had previously discovered LNM E1 compound used to kill prostate cancer. This time they have unlocked the capability of LNM family molecules by “mining” the inform...

Loom of Patent Expiry leads Bristol-Myers Squibb to nix 58 marketing jobs Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs—and, as a result, 58 workers will bid farewell to their jobs. The company is making changes to their HIV portfolio businessin anticipation of end-of-year ...